Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007

뉴스 본문을 불러오고 있어요.

Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007 | 웨이프 WAPE

Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007

기사 요약

관련 종목

댓글 —